Vaniqa cream 11,5% (eflornithine)
Vaniqa contains the active ingredient eflornithine which is approved for treatment of facial hirsutism in women. The cream is to be applied twice daily with intervals of at least eight hours, and the area should not be washed within four hours after application, if maximum effect is to be achieved. The first-line treatment of hirsutism caused by polycystic ovary syndrome (PCOS) is still cyproteron acetate in combination with ethinyl estradiol.
Generally seen, the effect studies have shown a successful result in 24-44 % of patients using Vaniqa, compared to 4-13 % in patients using only vehicle. An effect can be seen within eight weeks of treatment start, and further effect can be achieved with continuous treatment. The treatment is only documented for use in face and under the chin. The effect will decrease when treatment is stopped, and is gone after eight weeks. There appears to be an additive effect with concomitant laser treatment, but this is not included in the approved indication. No systemic adverse effects are seen, and the most frequent side effect is pricking and burning sensations in the skin. A month of treatment with Vaniqa costs about 400 Dkr. There is no reimbursement.